Pernix Commences Refinancing Transactions to Fortify Balance Sheet
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Pernix Therapeutics (PTX) Reports Prelim. Q2 Revenue of $33M-$35M
July 20, 2017 4:57 PM EDTPernix Therapeutics Holdings, Inc. (NASDAQ: PTX) today announced certain preliminary unaudited financial results for the second quarter ended June 30, 2017.
Second Quarter 2017 Preliminary Unaudited Financial Highlights:
Second quarter 2017 net revenues are expected to be between $33.0 million and $35.0 million, which would represent a decrease of between 5% and 10% versus second quarter 2016 net revenues of $36.7 million.Second quarter 2017 selling, general and administrative expense is expected to be between $18.0... More